| 产品名称： | OVB-3 OVB3 |
|---|---|
| 商品货号： | TS211173 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension, suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody cross-reacts with various normal and neoplastic tissues. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human ovarian carcinoma |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human ovarian carcinoma |
| Comments： | Animals were immunized with OVCAR-3 cells (see NIH:OVCAR-3, ATCC HTB-161). Spleen cells were fused with NS-1 myeloma cells. The antibody cross-reacts with various normal and neoplastic tissues. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) cells/ml and maintain between 1 X 10(5) and 1 X 10(6) cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2a and 2b , IgG2a; IgG2b |
| Name of Depositor： | The United States of America |
| U.S. Patent Number： | |
| References： | Willingham MC, et al. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc. Natl. Acad. Sci. USA 84: 2474-2478, 1987. PubMed: 3104916 Pearson JW, et al. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res. 49: 4990-4995, 1989. PubMed: 2504482 Fitzgerald DJ, et al. Monoclonal antibody against ovarian cancer cells (OVB-3). US Patent 4,806,494 dated Feb 21 1989 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | OVB-3 OVB3 |
|---|---|
| 商品货号： | TS211173 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension, suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody cross-reacts with various normal and neoplastic tissues. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human ovarian carcinoma |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human ovarian carcinoma |
| Comments： | Animals were immunized with OVCAR-3 cells (see NIH:OVCAR-3, ATCC HTB-161). Spleen cells were fused with NS-1 myeloma cells. The antibody cross-reacts with various normal and neoplastic tissues. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) cells/ml and maintain between 1 X 10(5) and 1 X 10(6) cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2a and 2b , IgG2a; IgG2b |
| Name of Depositor： | The United States of America |
| U.S. Patent Number： | |
| References： | Willingham MC, et al. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc. Natl. Acad. Sci. USA 84: 2474-2478, 1987. PubMed: 3104916 Pearson JW, et al. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res. 49: 4990-4995, 1989. PubMed: 2504482 Fitzgerald DJ, et al. Monoclonal antibody against ovarian cancer cells (OVB-3). US Patent 4,806,494 dated Feb 21 1989 |
